A paper by Drummond et al. (2023) examines how well being know-how evaluation our bodies cope with the problem of worth evaluation for cell and gene therapies (also referred to as Advanced Therapy Medicinal Products (ATMPs) in Europe). To do that the authors:
…undertook i) a focused assessment of the literature on the scientific and financial proof wants for these therapies, and ii) an in-depth evaluation of HTA reviews from 8 main jurisdictions for 9 cell and gene therapies in 10 indications, along with any related publicly obtainable paperwork on managed entry agreements and post-launch proof necessities.
The authors used a knowledge extraction type from Drummond et al. (2019).
The authors study these components and decide the share of which these components had been cited in a optimistic, destructive or impartial method.
Also of curiosity is that whereas some broader or societal worth components had been cited in ATMP worth evaluation, this was removed from ubiquitous.
The paper is attention-grabbing all through and you’ll be able to learn the complete paper right here.